Results 51 to 60 of about 386,203 (191)

Can COPD Exacerbations Be Picked Up Early via a Weekly Medication Question Through a Smartphone Application?

Frontiers in Rehabilitation Sciences, 2022
BackgroundExacerbations affect the disease trajectory of patients with COPD and result in an acute drop of functional status and physical activity. Timely detection of exacerbations by non-medical healthcare professionals is needed to counteract this ...
Astrid Blondeel, Heleen Demeyer, Heleen Demeyer, Sofie Breuls, Marieke Wuyts, Lies Glorie, Nikolaas De Maeyer, Wim Janssens, Wim Janssens, Thierry Troosters   +9 more
doaj   +1 more source

Percent Recovery Index Predicts Poor Asthma Control and Exacerbation in Adults

Journal of Asthma and Allergy, 2023
Lisha Kuang,1,* Cheng Ren,2,* Xiuqing Liao,2 Xiaobin Zhang,2 Xuegang Zhou2 1Department of Health Management Center, Chongqing University Fuling Hospital, Chongqing, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine,
Kuang L, Ren C, Liao X, Zhang X, Zhou X
doaj  

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study) [PDF]

, 2016
Background: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment
Beeh, Kai-Michael, Bjermer, Leif,, Derom, Eric, Echave-Sustaeta, José, Grönke, Lars, Hamilton, Alan, Lund University., Lund University., Zhai, Dongmei   +8 more
core   +2 more sources

The disruptive effects of COPD exacerbation-associated factors on epithelial repair responses

Frontiers in Immunology
IntroductionExacerbations of chronic obstructive pulmonary disease (COPD) increase mortality risk and can lead to accelerated loss of lung function. The increased inflammatory response during exacerbations contributes to worsening of airflow limitation ...
Rosa K. Kortekaas, Rosa K. Kortekaas, Kerstin E. Geillinger-Kästle, Rocío Fuentes-Mateos, Rocío Fuentes-Mateos, Roël van Orsoy, Roël van Orsoy, Nakaa Al-Alyan, Nakaa Al-Alyan, Janette K. Burgess, Janette K. Burgess, Reinoud Gosens, Reinoud Gosens   +12 more
doaj   +1 more source

Key toolkits of non-pharmacological management in COPD: during and beyond COVID-19

Frontiers in Bioscience-Landmark, 2021
Individuals with COPD are at higher risk of severe disease and mortality if they contract COVID-19. Shielding and social distancing have negatively impacted the delivery of routine care for COPD patients, which should be maintained to avoid further ...
Jaber S. Alqahtani, Saeed M Alghamdi, Abdulelah M Aldhahir, Malik Althobiani, Tope Oyelade   +4 more
doaj   +1 more source

Diaphragm Ultrasound is an Imaging Biomarker that Distinguishes Exacerbation Status from Stable Chronic Obstructive Pulmonary Disease

International Journal of COPD, 2022
Tai Joon An,1 Yeun Jie Yoo,2 Jeong Uk Lim,1 Wan Seo,3 Chan Kwon Park,1 Chin Kook Rhee,4 Hyoung Kyu Yoon1 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St.
An TJ, Yoo YJ, Lim JU, Seo W, Park CK, Rhee CK, Yoon HK   +6 more
doaj  

B-type natriuretic peptide as a predictor of severity in admitted patients with acute exacerbation of COPD

The Egyptian Journal of Bronchology, 2019
Background patients with acute AECOPD show an abrupt worsening of baseline ventricular function and pulmonary hypertension, using clear predictors or markers for severity in such patients is critical to be early stratified and properly managed.
Nasser K. Abdelnaby, Hassan A. Shabana, Waleed R. Arafat   +2 more
doaj   +1 more source

An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced Exacerbations of Lung Inflammation [PDF]

, 2013
Human rhinoviruses (HRV) cause the majority of common colds and acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Effective therapies are urgently needed, but no licensed treatments or vaccines currently exist.
A Papi, A van de Stolpe, AC Palmenberg, Alan Carruthers, Alexandra Nikonova, Alison Humbles, AM Randi, Andrew J. Leishman, Andrew Pekosz, CR Uncapher, D Wat, DC Pevear, DE Staunton, DJ Jackson, DJ Jackson, DJ Jackson, FG Hayden, FG Hayden, Gary R. McLean, J Bizzintino, J Corren, J Garbino, J Las Heras, JE Gern, JE Prince, Jie Zhu, JM Greve, Katherine A. Vousden, Katie Bernard, KB Weiss, KG Nicholson, Leila Gogsadze, Matthew A. Sleeman, Michael Dymond, MS Diamond, Musa Khaitov, Nathan W. Bartlett, Nicholas Glanville, NW Bartlett, P Mallia, Q Wang, Qing Zhu, R Fleischer, Rebecca Dunmore, RF Lemanske Jr, RH Dougherty, RM Owens, Roland Kolbeck, Ross P. Walton, RR Turner, Sebastian L. Johnston, SK Lau, SL Binford, Stephanie Traub, Ted Wells, Weidong Hao, YA Bochkov   +56 more
core   +3 more sources

Exacerbations and associated healthcare cost in patients with COPD in general practice

Monaldi Archives for Chest Disease, 2016
Background. Acute exacerbations are a characteristic clinical expression of chronic obstructive pulmonary disease (COPD). The objective of this study was to investigate the occurrence rate, management, and healthcare costs of exacerbations in patients ...
T.R.J. Schermer, C.G.J. Saris, W.J.H.M. Van den Bosch, N.H. Chavannes, C.P. Van Schayck, P.N.R. Dekhuijzen, C. Van Weel   +6 more
doaj   +1 more source

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils [PDF]

, 2017
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
Brusselle, Guy, Germinaro, Matthew, Weiss, Sivan, Zangrilli, James   +3 more
core   +2 more sources